Incidence of Dementia in Canada: A National Trend Analysis of Newly Diagnosed Cases
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Canadian dementia incidence declined modestly from 2007-2022, but significant sex, age, and regional disparities persist. Ongoing investment in dementia prevention and equitable care is crucial for the aging population.
Area Of Science
- Gerontology
- Epidemiology
- Public Health
Background
- Dementia is a growing neurocognitive disorder impacting global aging populations.
- Understanding dementia incidence trends is vital for Canada's healthcare planning due to its aging demographic.
- This study analyzes national dementia incidence trends in Canadians aged 65+ from 2007-2022.
Purpose Of The Study
- To examine national trends in age-standardized incidence rates of newly diagnosed dementia in Canada.
- To investigate trends including Alzheimer's disease in individuals aged 65 years and older.
- To identify sex, age, and regional disparities in dementia incidence.
Main Methods
- Retrospective, population-based trend analysis using the Canadian Chronic Disease Surveillance System (CCDSS).
- Utilized de-identified administrative health data (physician billing, hospital discharge) with ICD-9/ICD-10 codes for dementia ascertainment.
- Calculated age-standardized incidence rates using the 2011 Canadian standard population for fiscal years 2007-2008 to 2021-2022.
Main Results
- In 2022, crude dementia incidence was 1,323 per 100,000 population, higher in females (1,437) than males (1,194).
- Incidence increased significantly with age, with rates of 610 per 100,000 (65-79 years) and 3,669 per 100,000 (80+ years).
- Observed regional disparities, with Nunavut highest (1,700) and Saskatchewan lowest (1,154); age-standardized incidence declined overall from 2007-2022.
Conclusions
- Despite a modest decline in age-standardized dementia incidence (2007-2022), significant disparities by sex, age, and region persist in Canada.
- Emphasizes the need for continued investment in dementia prevention, equitable access to diagnosis, and tailored regional interventions.
- Coordinated public health strategies are essential to manage the growing burden of dementia in an aging population.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
The nurse documents nursing diagnoses and enters them into the patient record. The identified patient's nursing diagnosis is either written out with a plan of care or entered into the electronic health record.
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...